title: Rupatadine and levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety.
abstract: BACKGROUND
  Chronic Idiopathic Urticaria is difficult to treat due to its persistent debilitating symptoms. New generation anti-histaminics are first line treatment for this condition. The aim of this study is to compare efficacy and safety of rupatadine and levocetirizine in chronic idiopathic urticaria.
  
  
  METHODS
  A randomized, single blinded, single-centred, parallel group outdoor based clinical study was conducted in 70 patients of CIU to compare the two drugs. After initial clinical assessment and baseline investigations, rupatadine was prescribed to 35 patients and levocetirizine to another 35 patients for 4 weeks. At follow-up, the patients were re-evaluated and then compared using different statistical tools. Main outcome measures were DC eosinophil, Absolute Eosinophil Count (AEC), serum IgE, Total Symptom Score, Aerius Quality of Life Questionnaire score, and Global efficacy score.
  
  
  RESULTS
  Rupatadine significantly improved patients' clinical condition including symptom score from baseline to day 28. In rupatadine group, there was 27.9 percent decrease (P=0.027) in DC eosinophil, 35.6 percent decrease (P=0.036) in AEC, 15.3 percent decrease (P=0.024) in serum IgE, 28.2 percent decrease (P=0.02) in Total Symptom Scoring, and 27.3 percent decrease (P=0.006) in Aerius Quality of Life Questionnaire score. Global efficacy score of rupatadine was found to be significantly greater (P=0.009) than levocetirizine. The overall incidence of adverse drug reactions was also found to be less in rupatadine group.
  
  
  CONCLUSIONS
  Rupatadine is a better choice in CIU in comparison to levocetirizine due to better efficacy and safety profile.
authors: Department of Pharmacology, Prathima Institute of Medical Sciences, Karimnagar, Andhrapradesh, India. rituparnamaiti@rediffmail.com
authors: Rituparna
authors: R
authors: Maiti
authors: Jyothirmai
authors: J
authors: Jaida
authors: B N
authors: BN
authors: Raghavendra
authors: Prakash
authors: P
authors: Goud
authors: Idris
authors: I
authors: Ahmed
authors: Anuradha
authors: A
authors: Palani
mesh_terms: D000293:Adolescent; D000328:Adult; D017332:Cetirizine / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002908:Chronic Disease; D003533:Cyproheptadine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006633:Histamine Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D016037:Single-Blind Method; D016896:Treatment Outcome; D014581:Urticaria / Q000188:drug therapy*; D055815:Young Adult
chemical_list: D006633:Histamine Antagonists; C103639:rupatadine; D003533:Cyproheptadine; C472067:levocetirizine; D017332:Cetirizine